DK0984778T3 - Neuropeptid-Y-ligander - Google Patents

Neuropeptid-Y-ligander

Info

Publication number
DK0984778T3
DK0984778T3 DK97939524T DK97939524T DK0984778T3 DK 0984778 T3 DK0984778 T3 DK 0984778T3 DK 97939524 T DK97939524 T DK 97939524T DK 97939524 T DK97939524 T DK 97939524T DK 0984778 T3 DK0984778 T3 DK 0984778T3
Authority
DK
Denmark
Prior art keywords
neuropeptide
ligands
formula
agonists
regulators
Prior art date
Application number
DK97939524T
Other languages
English (en)
Inventor
Edward Gregor Vlad
Yufeng Hong
Lai Ling Anthony
Valenzuela Tompkins Eileen
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Application granted granted Critical
Publication of DK0984778T3 publication Critical patent/DK0984778T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97939524T 1996-08-23 1997-08-22 Neuropeptid-Y-ligander DK0984778T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2579196P 1996-08-23 1996-08-23
PCT/US1997/014854 WO1998007420A1 (en) 1996-08-23 1997-08-22 Neuropeptide-y ligands

Publications (1)

Publication Number Publication Date
DK0984778T3 true DK0984778T3 (da) 2002-09-16

Family

ID=21828075

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97939524T DK0984778T3 (da) 1996-08-23 1997-08-22 Neuropeptid-Y-ligander

Country Status (11)

Country Link
US (1) US6849733B1 (da)
EP (1) EP0984778B1 (da)
JP (1) JP2001502296A (da)
AT (1) ATE218859T1 (da)
AU (1) AU4159297A (da)
CA (1) CA2268051A1 (da)
DE (1) DE69713402T2 (da)
DK (1) DK0984778T3 (da)
ES (1) ES2176776T3 (da)
PT (1) PT984778E (da)
WO (1) WO1998007420A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
SE9802206D0 (sv) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
SE9802207D0 (sv) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
EP1033366A3 (en) * 1999-02-18 2000-12-27 Pfizer Products Inc. Amide derivatives useful as Neuropeptide Y (NPY) antagonists
US6355807B1 (en) 1999-08-24 2002-03-12 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
US6774243B2 (en) 1999-08-24 2004-08-10 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
JP2004522705A (ja) * 2000-10-30 2004-07-29 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アミジノ−尿素セロトニン受容体リガンドおよび組成物、その医薬的使用およびその合成方法
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
WO2003099818A1 (en) 2002-05-23 2003-12-04 Chiron Corporation Substituted quinazolinone compounds
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2523015A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
EP1680120A2 (en) 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
KR20060105785A (ko) 2003-11-19 2006-10-11 카이론 코포레이션 감소된 생체축적을 갖는 퀴나졸리논 화합물
JP4996926B2 (ja) 2004-02-05 2012-08-08 プロビオドルグ エージー グルタミニルシクラーゼの新規の阻害剤
AU2006235200A1 (en) * 2005-04-15 2006-10-19 Regenertech Pty Limited Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration
WO2007002220A2 (en) * 2005-06-21 2007-01-04 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as beta-secretase inhibitors
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7657504B2 (en) * 2006-10-10 2010-02-02 Microsoft Corporation User interface for displaying images of sights
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
RS55360B1 (sr) 2007-12-07 2017-03-31 Vertex Pharma Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
KR101790806B1 (ko) 2010-03-10 2017-11-20 프로비오드룩 아게 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
BR112017010406B1 (pt) 2014-11-18 2021-03-09 Vertex Pharmaceuticals Incorporated processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
JP6792636B2 (ja) * 2016-11-25 2020-11-25 日本曹達株式会社 グアニジン化合物および殺菌剤
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7583881A (en) * 1981-08-24 1983-03-08 Rorer International (Overseas) Inc. Promotion of feed efficiency in animals
AU7535681A (en) * 1981-08-24 1983-03-08 Rorer International (Overseas) Inc. Treatment of infections
US5380945A (en) * 1989-06-21 1995-01-10 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
ATE109979T1 (de) * 1990-03-30 1994-09-15 Heumann Pharma Gmbh & Co Verwendung von guanidinderivaten zur herstellung eines arzneimittels mit npy-antagonistischer wirkung.
US5482947A (en) * 1990-11-19 1996-01-09 Talley; John J. Retroviral protease inhibitors
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4301452A1 (de) * 1993-01-20 1994-07-21 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2701480B1 (fr) 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
AU3953795A (en) 1994-10-20 1996-05-15 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
SK57097A3 (en) 1994-11-07 1998-10-07 Pfizer Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands

Also Published As

Publication number Publication date
EP0984778B1 (en) 2002-06-12
US6849733B1 (en) 2005-02-01
ES2176776T3 (es) 2002-12-01
DE69713402D1 (de) 2002-07-18
CA2268051A1 (en) 1998-02-26
DE69713402T2 (de) 2002-11-07
JP2001502296A (ja) 2001-02-20
EP0984778A1 (en) 2000-03-15
WO1998007420A1 (en) 1998-02-26
AU4159297A (en) 1998-03-06
ATE218859T1 (de) 2002-06-15
EP0984778A4 (en) 2000-06-07
PT984778E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
DK0984778T3 (da) Neuropeptid-Y-ligander
RS49688B (sr) Novi derivat 3-aril-2- hidroksipropionske kiseline (i)
SK86699A3 (en) Nitrogen containing heteroaromatics as factor xa inhibitors
BR9808491A (pt) Compostos calcilìticos
DK0572166T3 (da) Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer
ATE228111T1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
DE69004692D1 (de) Kohlenwasserstoffzusammensetzungen und Zusätze dafür.
BG104670A (en) 4-(2-keto-1-benzimidazolinyl)piperidinne compounds as orl1-receptor agonists
IT1269176B (it) Eterobicicli ad attivita' fungicida
TR199901653T2 (xx) Fitalazinonlar.
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
SE0004245D0 (sv) Novel compounds and their use
PL310940A1 (en) Organic compounds
ATE245642T1 (de) Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
NO981393D0 (no) Guanidinoproteasehemmere
RS50002B (sr) Eletriptan hidrobromid monohidrat
DK1204659T3 (da) Serotonerge benzofuraner
BG103789A (en) Fungicidal compositions
GB2324091A (en) Metalloproteinase inhibitors
FR2693911B1 (fr) Nouvelles utilisations d'un appareillage d'électro-anesthésie.
EA199900534A1 (ru) Имидазопиридазины
TR200100133T2 (tr) FKBP İnhibitörleri
ES2103794T3 (es) Pirazolinas, pirazolidinas e hidrazinas artropodicidas.
IT1271443B (it) Derivati eterobiciclici ad attivita' fungicida